Cerity Partners
MRVI icon

Cerity Partners’s Maravai LifeSciences MRVI Stock Holding History

Cerity Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Buy
469,359
+18
+0% +$78 ﹤0.01% 1370
2026
Q1 		$1.33M Buy
469,341
+1,426
+0.3% +$4.83K ﹤0.01% 1702
2025
Q4 		$1.52M Buy
+467,915
New +$1.58M ﹤0.01% 1496
2024
Q4 		– Sell
-11,702
Closed -$97.2K – 2532
2024
Q3 		$97.2K Buy
+11,702
New +$101K ﹤0.01% 2427
2024
Q2 		– Sell
-13,938
Closed -$121K – 2338
2024
Q1 		$121K Buy
+13,938
New +$94.3K ﹤0.01% 2180
2022
Q4 		– Sell
-21,239
Closed -$542K – 1512
2022
Q3 		$542K Sell
21,239
-4,898
-19% -$123K 0.01% 690
2022
Q2 		$743K Buy
26,137
+2,055
+9% +$65.1K 0.01% 624
2022
Q1 		$850K Buy
+24,082
New +$807K 0.01% 474
2021
Q2 		– Sell
-15,000
Closed -$535K – 728
2021
Q1 		$535K Sell
15,000
-57
-0.4% -$1.89K 0.01% 437
2020
Q4 		$422K Buy
+15,057
New +$419K 0.01% 441

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Cerity Partners's MRVI Position: Q2 2026 in Review

Cerity Partners increased its Maravai LifeSciences (MRVI) stake by 0% in Q2 2026, buying an estimated $78 and bringing the position to 469,359 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Cerity Partners first reported a position in MRVI in Q4 2020 and has held it in 10 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Cerity Partners held 469,359 shares of Maravai LifeSciences worth $2.93M as of Q2 2026.
  • Cerity Partners bought 18 Maravai LifeSciences shares in Q2 2026, an estimated $78.
  • Maravai LifeSciences made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1370 holding.
  • Cerity Partners first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 10 quarters since.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.